1025716-99-7

Basic information

• Product Name: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate
• Synonyms: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate;Benzoic acid,3-[(aMinoiMinoMethyl)aMino]-4-Methyl-,Methyl ester,nitrate(1:1);Methyl 3-guanidino-4-Methylbenzoate Mononitrate;3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid methyl ester nitrate;3-[(aminoiminomethyl)amino]-4-methyl-benzoic acid;((aminoiminomethyl)amino)-4-methylbenzoic acid methyl ester nitrate;methyl 3-guanidino-4-methylbenzoate nitrate
• CAS NO: 1025716-99-7
• Molecular Formula: C₁₀H₁₃N₃O₂*HNO₃
• Molecular Weight: 270.24196
• Product Categories: Intermediates
• Mol File: 1025716-99-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate(1025716-99-7)
• EPA Substance Registry System: 3-[(aMinoiMinoMethyl)aMino]-4-Methylbenzoic acid Methyl ester Mononitrate(1025716-99-7)

Safety Data

• Hazardous Substances Data: 1025716-99-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Mibefradil is utilized as an antihypertensive agent for the treatment of hypertension. It operates by blocking calcium channels, leading to the relaxation of blood vessels and a consequent reduction in blood pressure.
Used in Cardiovascular Medicine:
In the treatment of angina pectoris, Mibefradil is employed to improve myocardial oxygen supply. By inhibiting calcium ion influx into cardiac myocytes, it helps to alleviate the symptoms of angina, a condition characterized by chest pain due to insufficient oxygen supply to the heart muscle.
However, it is important to note that Mibefradil has been discontinued in some countries due to potential side effects and drug interactions, which underscores the need for careful consideration and medical supervision when using this compound for treatment purposes.

Upstream product

• 420-04-2 CYANAMID 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 

Downstream Products

• 917392-54-2 methyl 4-methyl-3 -[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzoate 
• 1079911-30-0 {5-[5-(3-difluoromethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-2-methyl-phenyl}-(4-pyridin-3-yl-pyrimidin-2-yl)-amine 
• 1079904-27-0 [2-methyl-5-(6-trifluoromethyl-1H-benzoimidazol-2-yl)-phenyl]-(4-pyridin-3-yl-pyrimidin-2-yl)-amine 
• 641569-94-0 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid 
• 923288-95-3 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide hydrochloride 
• 641571-10-0 nilotinib 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF NILOTINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The present invention relates to an improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof, with high purity and yields.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).

COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFR alpha and PDGFR beta kinases

PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS

The invention provides a novel class of pyrimidine derivatives, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases.